1	High-Dose	High-Dose	B-NP	JJ	O	2	NMOD	0
2	celecoxib	celecoxib	I-NP	NN	O	8	NMOD	0
3	and	and	O	CC	O	8	NMOD	0
4	metronomic	metronomic	B-NP	JJ	O	8	NMOD	0
5	``	``	I-NP	``	O	8	NMOD	0
6	low-dose	low-dose	I-NP	JJ	O	8	NMOD	0
7	''	''	I-NP	''	O	8	NMOD	0
8	cyclophosphamide	cyclophosphamide	I-NP	NN	O	9	SUB	0
9	is	be	B-VP	VBZ	O	0	ROOT	0
10	an	an	B-NP	DT	O	14	NMOD	0
11	effective	effective	I-NP	JJ	O	14	NMOD	0
12	and	and	I-NP	CC	O	14	NMOD	0
13	safe	safe	I-NP	JJ	O	14	NMOD	0
14	therapy	therapy	I-NP	NN	O	9	PRD	19	therapy
15	in	in	B-PP	IN	O	14	NMOD	0
16	patients	patient	B-NP	NNS	O	15	PMOD	0
17	with	with	B-PP	IN	O	16	NMOD	0
18	relapsed	relapsed	B-NP	JJ	O	20	AMOD	0
19	and	and	I-NP	CC	O	20	AMOD	0
20	refractory	refractory	I-NP	JJ	O	22	NMOD	0
21	aggressive	aggressive	I-NP	JJ	O	22	NMOD	0
22	histology	histology	I-NP	NN	O	25	NMOD	0
23	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	25	NMOD	0
24	's	's	B-NP	POS	O	25	NMOD	0
25	lymphoma	lymphoma	I-NP	NN	O	17	PMOD	0
26	.	.	O	.	O	9	P	0

1	PURPOSE	PURPOSE	B-NP	NN	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Angiogenesis	Angiogenesis	B-NP	NN	O	4	SUB	3	Angiogenesis
4	is	be	B-VP	VBZ	O	1	NMOD	0
5	increased	increase	I-VP	VBN	O	4	VC	17	increased
6	in	in	B-PP	IN	O	5	VMOD	0
7	aggressive	aggressive	B-NP	JJ	O	8	NMOD	0
8	histology	histology	I-NP	NN	O	11	NMOD	0
9	non-Hodgkin	non-Hodgkin	B-NP	JJ	O	11	NMOD	0
10	's	's	B-NP	POS	O	11	NMOD	0
11	lymphoma	lymphoma	I-NP	NN	O	6	PMOD	0
12	and	and	O	CC	O	4	VMOD	0
13	may	may	B-VP	MD	O	4	VMOD	0
14	be	be	I-VP	VB	O	13	VC	0
15	a	a	B-NP	DT	O	16	NMOD	0
16	target	target	I-NP	NN	O	14	PRD	0
17	with	with	B-PP	IN	O	16	NMOD	0
18	selective	selective	B-NP	JJ	O	20	NMOD	0
19	cyclooxygenase-2	cyclooxygenase-2	I-NP	NN	B-protein	20	NMOD	0
20	inhibition	inhibition	I-NP	NN	O	23	NMOD	18	inhibition
21	and	and	O	CC	O	23	NMOD	0
22	metronomic	metronomic	B-NP	JJ	O	23	NMOD	0
23	chemotherapy	chemotherapy	I-NP	NN	O	17	PMOD	19	chemotherapy
24	.	.	O	.	O	4	P	0

1	EXPERIMENTAL	EXPERIMENTAL	B-NP	JJ	O	2	NMOD	0
2	DESIGN	DESIGN	I-NP	NN	O	0	ROOT	0
3	:	:	O	:	O	2	P	0
4	We	We	B-NP	PRP	O	5	SUB	0
5	assessed	assess	B-VP	VBD	O	2	NMOD	0
6	response	response	B-NP	NN	O	11	NMOD	0
7	,	,	O	,	O	11	P	0
8	toxicity	toxicity	B-NP	NN	O	11	NMOD	0
9	,	,	O	,	O	11	P	0
10	and	and	O	CC	O	11	NMOD	0
11	biomarkers	biomarker	B-NP	NNS	O	5	OBJ	0
12	of	of	B-PP	IN	O	11	NMOD	0
13	angiogenesis	angiogenesis	B-NP	NN	O	12	PMOD	3	angiogenesis
14	to	to	B-PP	TO	O	11	NMOD	0
15	low-dose	low-dose	B-NP	JJ	O	16	NMOD	0
16	cyclophosphamide	cyclophosphamide	I-NP	NN	O	20	NMOD	0
17	(	(	O	(	O	20	NMOD	0
18	50	50	B-NP	CD	O	19	AMOD	0
19	mg	mg	I-NP	NN	O	20	NMOD	0
20	p.o	p.o	I-NP	NN	O	14	PMOD	0
21	.	.	O	.	O	2	P	0

1	o.d.	o.d.	B-LST	LS	O	9	NMOD	0
2	)	)	O	)	O	1	DEP	0
3	and	and	O	CC	O	5	NMOD	0
4	high-dose	high-dose	B-NP	JJ	O	5	NMOD	0
5	celecoxib	celecoxib	I-NP	NN	O	9	NMOD	0
6	(	(	O	(	O	9	NMOD	0
7	400	400	B-NP	CD	O	9	NMOD	0
8	mg	mg	I-NP	NN	O	9	NMOD	0
9	p.o	p.o	I-NP	NN	O	0	ROOT	0
10	.	.	O	.	O	9	P	0

1	b.i.d.	b.i.d.	B-LST	LS	O	0	ROOT	0
2	)	)	O	)	O	1	DEP	0
3	in	in	B-PP	IN	O	1	VMOD	0
4	adult	adult	B-NP	JJ	O	5	NMOD	0
5	patients	patient	I-NP	NNS	O	3	PMOD	0
6	with	with	B-PP	IN	O	5	NMOD	0
7	relapsed	relapsed	B-NP	JJ	O	13	NMOD	0
8	or	or	I-NP	CC	O	13	NMOD	0
9	refractory	refractory	I-NP	JJ	O	10	AMOD	0
10	aggressive	aggressive	I-NP	JJ	O	13	NMOD	0
11	non-Hodgkin	non-Hodgkin	I-NP	JJ	O	13	NMOD	0
12	's	's	B-NP	POS	O	13	NMOD	0
13	lymphoma	lymphoma	I-NP	NN	O	6	PMOD	0
14	in	in	B-PP	IN	O	5	NMOD	0
15	a	a	B-NP	DT	O	20	NMOD	0
16	multicenter	multicenter	I-NP	JJ	O	20	NMOD	0
17	phase	phase	I-NP	NN	O	20	NMOD	0
18	II	II	I-NP	CD	O	20	NMOD	0
19	prospective	prospective	I-NP	JJ	O	20	NMOD	0
20	study	study	I-NP	NN	O	14	PMOD	0
21	.	.	O	.	O	1	P	0

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Thirty-two	Thirty-two	B-NP	CD	O	4	AMOD	0
4	of	of	B-PP	IN	O	1	NMOD	0
5	35	35	B-NP	CD	O	6	NMOD	0
6	patients	patient	I-NP	NNS	O	4	PMOD	0
7	(	(	O	(	O	13	DEP	0
8	median	median	B-NP	JJ	O	9	NMOD	0
9	age	age	I-NP	NN	O	12	NMOD	0
10	,	,	O	,	O	12	P	0
11	62	62	B-NP	CD	O	12	NMOD	0
12	years	year	I-NP	NNS	O	13	DEP	0
13	)	)	O	)	O	6	NMOD	0
14	are	be	B-VP	VBP	O	4	SBAR	0
15	evaluable	evaluable	B-ADJP	JJ	O	14	PRD	0
16	for	for	B-PP	IN	O	15	AMOD	0
17	response	response	B-NP	NN	O	16	PMOD	0
18	.	.	O	.	O	1	P	0

1	Patients	Patient	B-NP	NNS	O	2	SUB	0
2	had	have	B-VP	VBD	O	13	VMOD	0
3	primarily	primarily	I-VP	RB	O	2	VMOD	0
4	relapsed	relapse	I-VP	VBN	O	8	NMOD	0
5	diffuse	diffuse	B-NP	JJ	O	6	AMOD	0
6	large	large	I-NP	JJ	O	8	NMOD	0
7	B-cell	B-cell	I-NP	NN	O	8	NMOD	0
8	lymphoma	lymphoma	I-NP	NN	O	13	SUB	0
9	(	(	O	(	O	12	DEP	0
10	63	63	B-NP	CD	O	11	NMOD	0
11	%	%	I-NP	NN	O	12	DEP	0
12	)	)	O	)	O	8	NMOD	0
13	were	be	B-VP	VBD	O	0	ROOT	0
14	heavily	heavily	I-VP	RB	O	13	VMOD	0
15	pretreated	pretreate	I-VP	VBN	O	13	VC	19	pretreated
16	(	(	O	(	O	21	DEP	0
17	median	median	B-NP	NN	O	21	DEP	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	three	three	B-NP	CD	O	20	NMOD	0
20	regimens	regimen	I-NP	NNS	O	18	PMOD	0
21	)	)	O	)	O	15	VMOD	0
22	and	and	O	CC	O	30	NMOD	0
23	high	high	B-NP	JJ	O	24	NMOD	0
24	risk	risk	I-NP	NN	O	30	NMOD	0
25	(	(	O	(	O	30	NMOD	0
26	79	79	B-NP	CD	O	30	NMOD	0
27	%	%	I-NP	NN	O	30	NMOD	0
28	international	international	I-NP	JJ	O	30	NMOD	0
29	prognostic	prognostic	I-NP	JJ	O	30	NMOD	0
30	index	index	I-NP	NN	O	38	NMOD	0
31	,	,	O	,	O	30	P	0
32	greater	great	B-ADJP	JJR	O	30	NMOD	0
33	than	than	B-PP	IN	O	32	AMOD	0
34	or=2	or=2	B-NP	NN	O	33	PMOD	0
35	)	)	O	)	O	30	NMOD	0
36	and	and	O	CC	O	38	NMOD	0
37	34	34	B-NP	CD	O	38	NMOD	0
38	%	%	I-NP	NN	O	39	SUB	0
39	were	be	B-VP	VBD	O	15	VMOD	0
40	relapsed	relapse	I-VP	VBN	O	39	VC	0
41	after	after	B-PP	IN	O	40	VMOD	0
42	autologous	autologous	B-NP	JJ	O	45	NMOD	0
43	stem	stem	I-NP	NN	O	45	NMOD	0
44	cell	cell	I-NP	NN	O	45	NMOD	0
45	transplant	transplant	I-NP	NN	O	41	PMOD	19	transplant
46	.	.	O	.	O	13	P	0

1	With	With	B-PP	IN	O	14	VMOD	0
2	a	a	B-NP	DT	O	4	NMOD	0
3	median	median	I-NP	JJ	O	4	NMOD	0
4	follow-up	follow-up	I-NP	NN	O	1	PMOD	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	8.4	8.4	B-NP	CD	O	7	NMOD	0
7	months	month	I-NP	NNS	O	5	PMOD	0
8	,	,	O	,	O	14	P	0
9	the	the	B-NP	DT	O	13	NMOD	0
10	overall	overall	I-NP	JJ	O	13	NMOD	0
11	best	good	I-NP	JJS	O	13	NMOD	0
12	response	response	I-NP	NN	O	13	NMOD	0
13	rate	rate	I-NP	NN	O	14	SUB	0
14	is	be	B-VP	VBZ	O	0	ROOT	0
15	37	37	B-NP	CD	O	16	NMOD	0
16	%	%	I-NP	NN	O	14	PRD	0
17	(	(	O	(	O	29	DEP	0
18	2	2	B-NP	CD	O	23	NMOD	0
19	complete	complete	I-NP	JJ	O	23	NMOD	0
20	clinical	clinical	I-NP	JJ	O	23	NMOD	0
21	response/complete	response/complete	I-NP	JJ	O	23	NMOD	0
22	clinical	clinical	I-NP	JJ	O	23	NMOD	0
23	response	response	I-NP	NN	O	28	NMOD	0
24	unconfirmed	unconfirmed	B-ADJP	JJ	O	23	NMOD	0
25	and	and	O	CC	O	28	NMOD	0
26	9	9	B-NP	CD	O	28	NMOD	0
27	partial	partial	I-NP	JJ	O	28	NMOD	0
28	response	response	I-NP	NN	O	29	DEP	0
29	)	)	O	)	O	16	NMOD	0
30	,	,	O	,	O	16	P	0
31	with	with	B-PP	IN	O	16	NMOD	0
32	22	22	B-NP	CD	O	33	NMOD	0
33	%	%	I-NP	NN	O	31	PMOD	0
34	achieving	achieve	B-VP	VBG	O	33	NMOD	0
35	stable	stable	B-NP	JJ	O	36	NMOD	0
36	disease	disease	I-NP	NN	O	34	OBJ	0
37	.	.	O	.	O	14	P	0

1	Median	Median	B-NP	JJ	O	5	NMOD	0
2	overall	overall	I-NP	JJ	O	5	NMOD	0
3	and	and	I-NP	CC	O	5	NMOD	0
4	progression-free	progression-free	I-NP	JJ	O	5	NMOD	0
5	survivals	survival	I-NP	NNS	O	6	SUB	0
6	are	be	B-VP	VBP	O	0	ROOT	0
7	14.4	14.4	B-NP	CD	O	9	AMOD	0
8	and	and	I-NP	CC	O	9	AMOD	0
9	4.7	4.7	I-NP	CD	O	10	NMOD	0
10	months	month	I-NP	NNS	O	6	PRD	0
11	,	,	O	,	O	6	P	0
12	respectively	respectively	B-ADVP	RB	O	6	VMOD	0
13	.	.	O	.	O	6	P	0

1	The	The	B-NP	DT	O	4	NMOD	0
2	median	median	I-NP	JJ	O	4	NMOD	0
3	response	response	I-NP	NN	O	4	NMOD	0
4	duration	duration	I-NP	NN	O	5	SUB	0
5	was	be	B-VP	VBD	O	0	ROOT	0
6	8.2	8.2	B-NP	CD	O	7	NMOD	0
7	months	month	I-NP	NNS	O	5	PRD	0
8	.	.	O	.	O	5	P	0

1	The	The	B-NP	DT	O	4	NMOD	0
2	most	most	I-NP	RBS	O	3	AMOD	0
3	common	common	I-NP	JJ	O	4	NMOD	0
4	toxicity	toxicity	I-NP	NN	O	5	SUB	0
5	was	be	B-VP	VBD	O	18	VMOD	0
6	skin	skin	B-NP	NN	O	7	NMOD	0
7	rash	rash	I-NP	NN	O	5	OBJ	0
8	(	(	O	(	O	11	DEP	0
9	40	40	B-NP	CD	O	10	NMOD	0
10	%	%	I-NP	NN	O	11	DEP	0
11	)	)	O	)	O	7	NMOD	0
12	;	;	O	:	O	5	P	0
13	myelosuppression	myelosuppression	B-NP	NN	O	17	NMOD	0
14	and	and	I-NP	CC	O	17	NMOD	0
15	gastrointestinal	gastrointestinal	I-NP	JJ	O	17	NMOD	0
16	side	side	I-NP	NN	O	17	NMOD	0
17	effects	effect	I-NP	NNS	O	18	SUB	0
18	were	be	B-VP	VBD	O	0	ROOT	0
19	uncommon	uncommon	B-ADJP	JJ	O	18	PRD	0
20	.	.	O	.	O	18	P	0

1	Three	Three	B-NP	CD	O	2	NMOD	0
2	patients	patient	I-NP	NNS	O	3	SUB	0
3	developed	develop	B-VP	VBD	O	0	ROOT	0
4	deep	deep	B-NP	JJ	O	6	NMOD	0
5	vein	vein	I-NP	NN	O	6	NMOD	0
6	thromboses	thrombos	I-NP	NNS	O	11	NMOD	0
7	and	and	O	CC	O	11	NMOD	0
8	two	two	B-NP	CD	O	11	NMOD	0
9	heavily	heavily	I-NP	RB	O	10	AMOD	0
10	pretreated	pretreate	I-NP	VBN	O	11	NMOD	19	pretreated
11	patients	patient	I-NP	NNS	O	12	SUB	0
12	developed	develop	B-VP	VBD	O	3	VMOD	0
13	treatment-related	treatment-related	B-NP	JJ	O	16	NMOD	19	treatment
14	acute	acute	I-NP	JJ	O	16	NMOD	0
15	myelogenous	myelogenous	I-NP	JJ	O	16	NMOD	0
16	leukemia	leukemia	I-NP	NN	O	18	NMOD	0
17	or	or	I-NP	CC	O	18	NMOD	0
18	myelodysplasia	myelodysplasia	I-NP	NN	O	12	OBJ	0
19	after	after	B-PP	IN	O	12	VMOD	0
20	3.7	3.7	B-NP	CD	O	22	AMOD	0
21	and	and	I-NP	CC	O	22	AMOD	0
22	12	12	I-NP	CD	O	23	NMOD	0
23	months	month	I-NP	NNS	O	19	PMOD	0
24	of	of	B-PP	IN	O	23	NMOD	0
25	therapy	therapy	B-NP	NN	O	24	PMOD	19	therapy
26	.	.	O	.	O	3	P	0

1	Circulating	Circulate	B-VP	VBG	B-cell_type	3	NMOD	0
2	endothelial	endothelial	B-NP	JJ	I-cell_type	3	NMOD	0
3	cells	cell	I-NP	NNS	I-cell_type	6	NMOD	0
4	and	and	O	CC	O	6	NMOD	0
5	their	their	B-NP	PRP$	O	6	NMOD	0
6	precursors	precursor	I-NP	NNS	O	7	SUB	0
7	declined	decline	B-VP	VBD	O	0	ROOT	0
8	and	and	I-VP	CC	O	7	VMOD	0
9	remained	remain	I-VP	VBD	O	7	VMOD	0
10	low	low	B-ADJP	JJ	O	9	PRD	0
11	in	in	B-PP	IN	O	10	AMOD	0
12	responders	responder	B-NP	NNS	O	11	PMOD	0
13	,	,	O	,	O	7	P	0
14	whereas	whereas	B-PP	IN	O	7	VMOD	0
15	plasma	plasma	B-NP	NN	O	19	NMOD	0
16	vascular	vascular	I-NP	JJ	O	15	AMOD	0
17	endothelial	endothelial	I-NP	JJ	O	15	AMOD	0
18	growth	growth	I-NP	NN	O	19	NMOD	0
19	factor	factor	I-NP	NN	O	27	NMOD	0
20	trended	trend	B-VP	VBN	O	19	NMOD	0
21	to	to	I-VP	TO	O	22	VMOD	0
22	decline	decline	I-VP	VB	O	20	VMOD	18	decline
23	in	in	B-PP	IN	O	22	VMOD	0
24	responding	respond	B-VP	VBG	O	25	NMOD	0
25	patients	patient	B-NP	NNS	O	23	PMOD	0
26	but	but	O	CC	O	27	NMOD	0
27	increase	increase	B-NP	NN	O	14	PMOD	17	increase
28	in	in	B-PP	IN	O	27	NMOD	0
29	nonresponders	nonresponder	B-NP	NNS	O	28	PMOD	0
30	.	.	O	.	O	7	P	0

1	Trough	Trough	B-PP	IN	O	0	ROOT	0
2	celecoxib	celecoxib	B-NP	NN	O	3	NMOD	0
3	levels	level	I-NP	NNS	O	4	SUB	0
4	achieved	achieve	B-VP	VBD	O	1	SBAR	0
5	targeted	target	I-VP	VBN	O	4	VMOD	18	targeted
6	``	``	B-NP	``	O	9	NMOD	0
7	antiangiogenic	antiangiogenic	I-NP	JJ	O	9	NMOD	3	angiogenic
8	''	''	I-NP	''	O	9	NMOD	0
9	levels	level	I-NP	NNS	O	5	OBJ	0
10	.	.	O	.	O	1	P	0

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	0
3	Low-dose	Low-dose	B-NP	JJ	O	4	NMOD	0
4	cyclophosphamide	cyclophosphamide	I-NP	NN	O	7	NMOD	0
5	and	and	O	CC	O	7	NMOD	0
6	high-dose	high-dose	B-NP	JJ	O	7	NMOD	0
7	celecoxib	celecoxib	I-NP	NN	O	8	SUB	0
8	is	be	B-VP	VBZ	O	1	NMOD	0
9	well	well	I-VP	RB	O	8	VMOD	0
10	tolerated	tolerate	I-VP	VBN	O	8	VC	0
11	and	and	O	CC	O	10	DEP	0
12	active	active	B-ADJP	JJ	O	10	PRD	0
13	in	in	B-PP	IN	O	10	VMOD	0
14	pretreated	pretreate	B-NP	VBN	O	18	NMOD	19	pretreated
15	aggressive	aggressive	I-NP	JJ	O	18	NMOD	0
16	non-Hodgkin	non-Hodgkin	I-NP	JJ	O	18	NMOD	0
17	's	's	B-NP	POS	O	18	NMOD	0
18	lymphoma	lymphoma	I-NP	NN	O	13	PMOD	0
19	.	.	O	.	O	1	P	0

1	Close	Close	B-NP	JJ	O	2	NMOD	0
2	surveillance	surveillance	I-NP	NN	O	9	SUB	0
3	for	for	B-PP	IN	O	2	NMOD	0
4	arterial	arterial	B-NP	JJ	O	8	NMOD	0
5	and	and	I-NP	CC	O	8	NMOD	0
6	venous	venous	I-NP	JJ	O	8	NMOD	0
7	thrombotic	thrombotic	I-NP	JJ	O	8	NMOD	0
8	events	event	I-NP	NNS	O	3	PMOD	0
9	is	be	B-VP	VBZ	O	0	ROOT	0
10	recommended	recommend	I-VP	VBN	O	9	VC	0
11	.	.	O	.	O	9	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	decline	decline	I-NP	NN	O	9	NMOD	18	decline
3	in	in	B-PP	IN	O	2	NMOD	0
4	circulating	circulate	B-VP	VBG	B-cell_type	6	NMOD	0
5	endothelial	endothelial	B-NP	JJ	I-cell_type	6	NMOD	0
6	cells	cell	I-NP	NNS	I-cell_type	3	PMOD	0
7	and	and	O	CC	O	9	NMOD	0
8	their	their	B-NP	PRP$	O	9	NMOD	0
9	precursors	precursor	I-NP	NNS	O	10	SUB	0
10	suggests	suggest	B-VP	VBZ	O	0	ROOT	0
11	that	that	B-SBAR	IN	O	10	VMOD	0
12	this	this	B-NP	DT	O	13	NMOD	0
13	combination	combination	I-NP	NN	O	14	SUB	0
14	may	may	B-VP	MD	O	11	SBAR	0
15	be	be	I-VP	VB	O	14	VC	0
16	working	work	I-VP	VBG	O	15	PRD	0
17	by	by	B-PP	IN	O	16	VMOD	0
18	inhibiting	inhibit	B-VP	VBG	O	17	PMOD	18	inhibiting
19	angiogenesis	angiogenesis	B-NP	NN	O	18	OBJ	3	angiogenesis
20	but	but	O	CC	O	10	VMOD	0
21	should	should	B-VP	MD	O	10	VMOD	0
22	be	be	I-VP	VB	O	21	VC	0
23	validated	validate	I-VP	VBN	O	22	VC	0
24	in	in	B-PP	IN	O	23	VMOD	0
25	a	a	B-NP	DT	O	28	NMOD	0
26	larger	large	I-NP	JJR	O	28	NMOD	0
27	patient	patient	I-NP	NN	O	28	NMOD	0
28	sample	sample	I-NP	NN	O	24	PMOD	0
29	.	.	O	.	O	10	P	0

